GKV Capital Management Co. Inc. Sells 15,332 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• GKV Capital Management Co. Inc. has significantly reduced its stake in Eli Lilly and Company by selling 15,332 shares, resulting in ownership of only 130 shares valued at $107,000.
• During the first quarter, other institutional investors like WestEnd Advisors LLC and Citizens National Bank Trust Department increased their holdings by 210% and 180% respectively, indicating a shift in investment interest.
• Analysts have varied opinions on Eli Lilly's stock, with the consensus rating at "Moderate Buy" and an average price target of $977.65, though some firms have adjusted their ratings lower in recent reports.

GKV Capital Management Co. Inc. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 99.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 130 shares of the company's stock after selling 15,332 shares during the period. GKV Capital Management Co. Inc.'s holdings in Eli Lilly and Company were worth $107,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LLY. Knightsbridge Asset Management LLC increased its position in shares of Eli Lilly and Company by 1.9% during the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares during the last quarter. LS Investment Advisors LLC boosted its stake in shares of Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after buying an additional 40 shares during the period. Prism Advisors Inc. purchased a new stake in Eli Lilly and Company during the first quarter worth approximately $207,000. CSM Advisors LLC lifted its stake in Eli Lilly and Company by 30.6% during the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after purchasing an additional 245 shares during the last quarter. Finally, Hemington Wealth Management increased its position in Eli Lilly and Company by 14.4% during the first quarter. Hemington Wealth Management now owns 985 shares of the company's stock worth $813,000 after buying an additional 124 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Company insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. UBS Group dropped their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Cantor Fitzgerald set a $825.00 price objective on Eli Lilly and Company and gave the company an "overweight" rating in a research report on Wednesday. Finally, Guggenheim dropped their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $964.88.

Eli Lilly and Company Stock Up 2.7%

Shares of LLY stock traded up $18.58 on Friday, reaching $701.51. 8,097,645 shares of the company's stock traded hands, compared to its average volume of 4,162,790. The company has a market capitalization of $663.95 billion, a P/E ratio of 45.85, a price-to-earnings-growth ratio of 0.93 and a beta of 0.44. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business's 50 day moving average price is $765.92 and its two-hundred day moving average price is $795.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the firm earned $3.92 earnings per share. The business's revenue for the quarter was up 37.6% on a year-over-year basis. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.9%. Eli Lilly and Company's payout ratio is presently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.